Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors

Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors

<p>Supplementary Table S1 STARS Scores</p>

Сохранить в:

Библиографические подробности
Главный автор:	Clare F. Malone (14960925) (author)
Другие авторы:	Minjee Kim (14960928) (author), Gabriela Alexe (14960931) (author), Kathleen Engel (14960934) (author), Alexandra B. Forman (14960937) (author), Amanda Robichaud (14960940) (author), Amy Saur Conway (14960943) (author), Amy Goodale (14960946) (author), Ashleigh Meyer (14960949) (author), Delan Khalid (14960952) (author), Allen Thayakumar (14960955) (author), John M. Hatcher (14960958) (author), Nathanael S. Gray (14940987) (author), Federica Piccioni (14960961) (author), Kimberly Stegmaier (14960964) (author)
Опубликовано:	2025
Предметы:	Cancer Therapeutic Research and Development Drug Targets Protein kinase & phosphatase drug targets Pediatric Cancers Translational Research
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
по: Clare F. Malone (14960925)
Опубликовано: (2025)

Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
по: Clare F. Malone (14960925)
Опубликовано: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
по: Katie E. Hebron (15046889)
Опубликовано: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
по: Katie E. Hebron (15046889)
Опубликовано: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
по: Katie E. Hebron (15046889)
Опубликовано: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
по: Katie E. Hebron (15046889)
Опубликовано: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
по: Katie E. Hebron (15046889)
Опубликовано: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
по: Katie E. Hebron (15046889)
Опубликовано: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
по: Katie E. Hebron (15046889)
Опубликовано: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
по: Srivandana Akshintala (16610490)
Опубликовано: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
по: Srivandana Akshintala (16610490)
Опубликовано: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
по: Anne-Florence Blandin (15056366)
Опубликовано: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
по: Anne-Florence Blandin (15056366)
Опубликовано: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
по: Anne-Florence Blandin (15056366)
Опубликовано: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
по: Anne-Florence Blandin (15056366)
Опубликовано: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
по: Anne-Florence Blandin (15056366)
Опубликовано: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
по: Anne-Florence Blandin (15056366)
Опубликовано: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
по: Anne-Florence Blandin (15056366)
Опубликовано: (2025)

Supplementary Video 1 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
по: Debarati Mukherjee (15134436)
Опубликовано: (2025)

Supplementary Video 2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
по: Debarati Mukherjee (15134436)
Опубликовано: (2025)

Supplementary Video 3 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
по: Debarati Mukherjee (15134436)
Опубликовано: (2025)

Supplementary Video 4 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
по: Debarati Mukherjee (15134436)
Опубликовано: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Supplementary Dataset S8 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
по: Cara Abecunas (14960274)
Опубликовано: (2025)

Table S3 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
по: Gia-Buu Tran (16437051)
Опубликовано: (2025)

Table S4 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
по: Gia-Buu Tran (16437051)
Опубликовано: (2025)

Table S5 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
по: Gia-Buu Tran (16437051)
Опубликовано: (2025)

Supplementary Table S1 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
по: Gia-Buu Tran (16437051)
Опубликовано: (2025)

Supplementary Table S2 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
по: Gia-Buu Tran (16437051)
Опубликовано: (2025)

Supplementary Dataset S1 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
по: Cara Abecunas (14960274)
Опубликовано: (2025)

Supplementary Dataset S2 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
по: Cara Abecunas (14960274)
Опубликовано: (2025)

Supplementary Dataset S3 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
по: Cara Abecunas (14960274)
Опубликовано: (2025)

Supplementary Dataset S4 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
по: Cara Abecunas (14960274)
Опубликовано: (2025)

Supplementary Dataset S5 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
по: Cara Abecunas (14960274)
Опубликовано: (2025)

Supplementary Dataset S6 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
по: Cara Abecunas (14960274)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_vnq8aqnu0maf9124l36ska7gmi